Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/11/21
End: 06/24/22
Due: 06/24/23
Phase: N/A
Priority: Normal
Start: 06/26/18
End: 11/09/23
Due: 11/09/24
Phase: N/A
Priority: Normal
Start: 03/31/15
End: 12/05/19
Due: 12/05/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | NCT04589832 | Arkadiusz Z. Dudek, MD | user2@example.com | None | 2021-01-11 | 2022-06-24 | 2023-06-24 | - | - | 2025-07-14 |
| Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma | NCT03502746 | Arkadiusz Z. Dudek, MD | user2@example.com | None | 2018-06-26 | 2023-11-09 | 2024-11-09 | - | - | 2025-07-14 |
| Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: | NCT02348008 | Arkadiusz Z. Dudek, MD | user2@example.com | None | 2015-03-31 | 2019-12-05 | 2020-12-05 | - | - | 2025-07-14 |